High functional bispecific antibody
AssigneeTohoku Univeristy
InventorsIzumi Kumagai, Ryutaro Asano
Life of this patent
Estimating the term…
Abstract
[Problem] The purpose of the present invention is to provide a bispecific antibody that is structurally stable, and can show alone a sufficient effect without the co-administration of activated lymphocyte (T-LAK). [Solution] The present invention is therefore related to a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having one of the following structures (i)-(vi) in Claim 1, wherein the 5H, 5L, OH and OL have an amino acid sequence represented by SEQ ID Nos 25, 26, 27 and 28, respectively.
Claims6
A humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3;
- comprising one of the following structures:
- (i) a tetravalent antibody comprising two single-chain polypeptides of (5L5H)-(a peptide linker)-(OHOL), and wherein the single-chain polypeptides are bonded to two Fc regions of a human antibody via each hinge region;
- (ii) a tetravalent antibody comprising four single-chain polypeptides, each comprising a VH and a VL region, wherein both of the two VH and two VL regions are replaced by:
- a single-chain Fv (5HL) polypeptide, which comprises humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and
- a single-chain Fv (OHL) polypeptide, which comprises humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3,
- respectively, or vice versa;
- or
- (iii) (5L5H)-(a peptide linker)-(OHOL),
- wherein the 5H, 5L, OH and OL have the amino acid sequence of SEQ ID NO:
- 25, 26, 27 and 28, respectively.
Dependencies are inferred from the claim text.